PA-BOOMI
13.6.2024 10:01:37 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced findings of a new global study.1 The IDC InfoBrief, sponsored by IFS and Boomi, reveals that aging, monolithic systems, and a lack of technological understanding at the executive level limit organizational agility and responsiveness to disruptions. The research also identified that having a composable strategy is key for organizations to overcome these challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613200694/en/
Boomi Research Reveals Composability Essential to Overcome Legacy System Challenges in Enterprises (Graphic: Business Wire)
The study polled over 1,000 C-level respondents across 12 countries in Europe, North America, Middle East, Africa, and Asia Pacific. It found that legacy technology platforms and unfamiliarity with the essential role Application Programming Interfaces (APIs) and composability play in unlocking business data are combining to hamper insights and transformation.
The widely acknowledged risks of not transitioning to composable applications have become even more pressing against the backdrop of current domestic and international upheavals. Recent developments such as Brexit, world issues, and the escalating cost-of-living crises have highlighted the deficiencies of outdated technologies.
While most businesses believe they have withstood the last three years of disruption, leaders report that working capital and inventory imbalances (56%), volatile demand (53%), and unpredictable supply chains (48%) had been their biggest challenges. Respondents also pointed to legacy applications (60%), lack of integration (48%), and inflexible/monolithic applications (43%) as hindering efforts to overcome these challenges - impacting the efficiency with which they can mitigate risks.
The research also revealed that the consequences of outdated technology platforms are being felt by businesses, with reports of limited visibility into operational processes (24%) and poor internal collaboration (18%). These findings suggest that companies struggle to use their data in long-term planning, hampering business agility and the ability to respond to future disruptions effectively.
With more than two-fifths (41%) of organizations lacking a composable strategy, the risk of stagnation and mounting technical debt is glaring. While the value of a composable architecture is well understood by over 70% of the C-suite respondents with business and functional responsibilities, the Board level professionals lag in their understanding - only 19% are clear on the value composability creates. This gulf between senior level executives points to a need for education and clearer business cases that highlight composability’s short, medium, and long-term value.
“This research sends a clear message to executives: To remain competitive, increase agility, and drive productivity across their entire business, composability is key,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “Speed to realizing value requires a strong data foundation and a mature cloud strategy as prerequisites to the adoption of other advanced technologies.”
Encouragingly, 89% of respondents identified API-driven innovation as a key component of composability with over half (51%) pointing to seamless integration between process workflows, and 37% to the importance of single-platform solutions. As well as highlighting the essential role of APIs in creating adaptable and flexible business systems, these findings support the notion that the future of business applications is composable.
In terms of technology preferences, APIs lead the way with 82% of respondents emphasizing their significance, followed by Artificial Intelligence (45%) and Machine Learning (40%). The research indicated that supply chain (51%), procurement (47%), and customer service and support (40%) are the top areas organizations believe they would benefit from application composability.
Despite the recognized importance of composability, the challenges identified in the research highlight the need for broader organizational alignment and clarity in technological direction to fully leverage the advantages of a composable architecture, where APIs play a foundational role.
Nevertheless, the survey data does reveal a significant trend towards investing in composing workflows with multiple products using APIs. Twenty-two percent of respondents reported to be actively pursuing this approach, reflecting a strategic move towards leveraging APIs for integrating diverse systems and applications to drive efficiency and innovation, and eliminate waste.
Macosky concluded: “Inertia in moving to the cloud or formulating a clear composability strategy is likely to prevent businesses from unlocking the full value of AI and machine learning technology. The challenge for organizations now is to realize value pervasively. However, they must overcome considerable barriers, such as the lack of understanding of composability’s value at the executive level and inadequate progression within cloud journeys. It should therefore come as little surprise that the CIO and CTO are the primary champions for composability.”
Additional Resources
- Download the IDC InfoBrief, sponsored by IFS and Boomi, a Global Study of Composability in Enterprise Software and Evolving Business Needs.
- Watch this webinar that explores the findings of the study with guest speakers from IDC, Boomi, and IFS.
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
____________________________
1 IDC InfoBrief, sponsored by IFS and Boomi, Global Study of Composability in Enterprise Software and Evolving Business Needs, doc #US51992524, April 2024. In December 2023, over 1,000 senior business decision makers across 12 countries were polled from the manufacturing, energy and utilities, aerospace and defense, construction and engineering, telecoms, and service industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613200694/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
